Constellium: very strong Q4 2025 results with the momentum continuing into H1 2026|Eramet publishes weak results for 2025 but takes radical measures to rapidly improve its financial structure, notably with a plan to strengthen its equity capital by € 500m|AF-KLM: Unit costs under control enabling good profitability levels|
Constellium: very strong Q4 2025 results with the momentum continuing into H1 2026|Eramet publie de faibles résultats 2025 mais prend des mesures radicales pour améliorer rapidement la structure financière, notamment avec un projet de renforcement des fonds propres de 500 m EUR|AF-KLM: Unit costs under control enabling good profitability levels|
AEGON: Uneventful results, US weaker, underlying OCG in line / Air France-KLM: Productivity gains starting to filter through / Arcadis: Weak revenues and EBITA, but strong NWC / Ascencio: Results in line, no concerns on Carrefour Belgium exposure / Azelis: Persisting softness in 4Q25, continued focus on costs and cash / BAM Group: Solid 2H25 results, 2026 outlook in line / Belgian telecoms: Telenet improved net adds, to relist as part of Ziggo in 2027, Liberty to sell half of its 66% Wyre stake ...
IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India Louvain-la-Neuve, Belgium – 19 February 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-en...
Aegon reports second half year 2025 results Schiphol, February 19, 2026 - Please click to access all 2H 2025 results related documents 2H 2025 Financial highlights Net result of EUR 375 million, a decrease compared with EUR 741 million in the second half of 2024, as growth in the operating result is offset by non-operating items and other charges. Full-year 2025 net result of EUR 980 million, up 45% compared with 2024 Operating result of EUR 858 million, up 11% compared with the second half of 2024 driven by an increase across all business units, reflecting commercial momentum and favor...
IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), l'un des principaux fabricants et distributeurs indiens de fluorodéoxyglucose (FDG) et de radiopharmaceutiques pour la tomographie par émission de positons (TEP), ont signé un contrat pour la livraison et l'i...
Euronext publishes Q4 and full year 2025 results Euronext publishes Q4 and full year 2025 results In 2025, Euronext delivered another year of double-digit growth, driven by the expansion of non-volume-related businesses, resilient trading, clearing revenues and cost discipline. Euronext will accelerate the execution of its strategic plan in 2026. Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 18 February 2026 – Euronext, the leading European capital market infrastructure, today publishes its results for the fourth quarter and full year 2025. Full year 2025 underlyin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.